Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ligand Pharmaceuticals Incorporated - Common Stock
(NQ:
LGND
)
190.36
+1.29 (+0.68%)
Streaming Delayed Price
Updated: 12:11 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ligand Pharmaceuticals Incorporated - Common Stock
< Previous
1
2
3
4
Next >
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year
↗
November 18, 2025
Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.
Via
Investor's Business Daily
This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know
↗
November 17, 2025
A high-conviction fund just trimmed one of its biggest winners—here’s what long-term investors should make of the move.
Via
The Motley Fool
Topics
Regulatory Compliance
Why One Small-Cap Fund Bought $11 Million in Cellebrite Stock Last Quarter
↗
November 17, 2025
A specialist small-cap fund just doubled down on a digital-intelligence company that's underperforming the broader market.
Via
The Motley Fool
This Fund Cut $7.3 Million of Atlas Energy Stock as the Company Suspends Its Dividend to Help Fuel Growth
↗
November 17, 2025
One fund just took a step back from a struggling energy name—right as the company suspended its dividend to fund future growth.
Via
The Motley Fool
Topics
Economy
Regulatory Compliance
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviews
↗
December 11, 2024
Via
Benzinga
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch
↗
November 07, 2025
Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.
Via
Benzinga
Ligand (LGND) Q3 2025 Earnings Call Transcript
↗
November 06, 2025
Ligand (LGND) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
November 06, 2025
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....
Via
MarketMinute
Topics
Intellectual Property
A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals
↗
November 08, 2024
Via
Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Surges on Strong Q3 2025 Earnings Beat and Raised Guidance
↗
November 06, 2025
Ligand (LGND) smashed Q3 2025 earnings estimates, driven by 47% royalty growth. The company also raised its full-year 2025 revenue and EPS guidance.
Via
Chartmill
Topics
Earnings
What's Next: Ligand Pharmaceuticals's Earnings Preview
↗
November 05, 2025
Via
Benzinga
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
September 22, 2025
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter...
Via
MarketMinute
Topics
Artificial Intelligence
Intellectual Property
What Analysts Are Saying About Ligand Pharmaceuticals Stock
↗
September 02, 2025
Via
Benzinga
Ligand (LGND) Q2 Revenue Jumps 15%
↗
August 07, 2025
Via
The Motley Fool
Topics
Intellectual Property
Ligand Pharmaceuticals (NASDAQ:LGND) Surpasses Q2 2025 Earnings Estimates with Strong Royalty Growth
↗
August 07, 2025
Ligand Pharmaceuticals (LGND) beat Q2 2025 earnings estimates with strong royalty growth, raising full-year guidance. Stock dipped slightly pre-market but gained 16.3% over the past month.
Via
Chartmill
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts
↗
July 10, 2025
The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.
Via
Stocktwits
Topics
Government
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease
↗
July 10, 2025
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.
Via
Benzinga
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
↗
July 09, 2025
Via
Benzinga
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings
↗
April 17, 2025
Via
Benzinga
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated
↗
April 17, 2025
Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.
Via
Stocktwits
Dow Falls Over 1%; US Initial Jobless Claims Decline
↗
April 17, 2025
Via
Benzinga
Topics
Stocks
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
↗
April 17, 2025
Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.
Via
Benzinga
Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy
↗
April 10, 2025
Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.
Via
Benzinga
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
April 10, 2025
Via
Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
↗
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
↗
December 09, 2024
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Via
Investor's Business Daily
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
